Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
NCT07187388 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-12-04
Summary
The goal of this clinical trial is to evaluate the impact of non-invasive electrical stimulation, when placed on the facial muscles can reduce facial pain and improve jaw mobility, and chewing in individuals with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS). The secondary goal is to evaluate the impact of non-invasive electrical stimulation on patient reported difficulty performing oral hygiene tasks in individuals with ALS and PLS. Participants will attend one in-person clinic visit and participate in one telephone interview 24 hours after the treatment. The clinic visit will include pre-intervention assessments, a single 30-minute treatment of electrical stimulation followed by post-intervention assessments.
The assessments will include a self-rating of jaw and facial pain, a range of motion test where participants will be asked to open their jaw as wide and as far to the side as possible, and a chewing efficiency test using a saltine cracker. Twenty-four hours later, participants will receive a follow-up phone call to self-rate their facial pain and report any difficulty performing oral hygiene tasks.
The treatment consists of a single 30-minute electrical stimulation session. Electrode pads will be placed on the participant's facial region, specifically over the masseter muscle belly and the TMJ area, while the participant is seated comfortably. The pads will be connected to an FDA-approved electrical stimulator, and the current will be adjusted to the participant's comfort level. Once set, the participant will remain seated for 30 minutes. At the end of the session, the stimulator will be turned off and the electrode pads removed.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Primary Lateral Sclerosis (PLS)
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
- DEVICE
-
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on. Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. The 30 minute TENS intervention will then take place.
Sponsors & Collaborators
-
Nova Southeastern University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-30
- Primary Completion
- 2026-08-13
- Completion
- 2026-08-13
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function
NCT02408900 ·Status: COMPLETED
-
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)
NCT01521728 ·Status: COMPLETED ·Phase: NA
-
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00420719 ·Status: UNKNOWN ·Phase: NA
-
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
NCT03334786 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis
NCT02286011 ·Status: UNKNOWN ·Phase: PHASE1
-
Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis
NCT02447952 ·Status: COMPLETED ·Phase: NA
-
Surface EMG and Ultrasound in MND
NCT05314348 ·Status: COMPLETED ·Phase: NA
-
Tongue-strengthening Exercises in People With ALS.
NCT07295990 ·Status: RECRUITING ·Phase: NA
-
Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)
NCT00580593 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
NCT04632225 ·Status: COMPLETED ·Phase: PHASE2
-
Innovative Ultrasound Technology in Neuromuscular Disease
NCT02104921 ·Status: COMPLETED
-
Fatigue in Patients With Amyotrophic Lateral Sclerosis
NCT04468191 ·Status: WITHDRAWN ·Phase: NA
-
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
NCT02917681 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
NCT02017912 ·Status: COMPLETED ·Phase: PHASE2
-
CuATSM Compared With Placebo for Treatment of ALS/MND
NCT04082832 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx
NCT03986671 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
NCT00415519 ·Status: COMPLETED ·Phase: PHASE3
-
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
NCT05663008 ·Status: RECRUITING
-
A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral
NCT02290886 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
NCT06391645 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients
NCT05139342 ·Status: UNKNOWN ·Phase: NA
-
Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases
NCT04956822 ·Status: UNKNOWN
-
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
NCT01492686 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00424463 ·Status: COMPLETED ·Phase: PHASE3
-
Digital Assessment of Speech and Fine Motor Control in ALS
NCT06315673 ·Status: RECRUITING